ArticleJournal for immunotherapy of cancer2025
PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite breakthroughs in immune checkpoint blockade (ICB) for advanced hepatocellular carcinoma (HCC), tumor immune evasion remains a major limitation to immunotherapy efficacy. PTEN-induced putative kinase 1 (PINK1) has highlighted roles in immune system regulation and tumor progression, but its specific role in HCC and impact on ICB response remains unclear. This study aimed to elucidate how PINK1 dysfunction enables HCC adaptation to ICB-induced immune attacks and identify potential therapeutic targets.
methodsOnline patient dataset analyses were performed to evaluate the impact of reduced PINK1 expression on clinical prognosis in HCC. An orthotopic HCC tumor cell mouse model was established. Single-cell RNA sequencing and flow cytometry were employed to explore the immune characteristics and remodeling of the tumor microenvironment in PINK1-deficient HCC. Neutrophils and T cells were isolated, stimulated, and/or cultured for ex vivo functional assays. Gene Expression Omnibus database analyses were performed to identify key genes involved in HCC resistance to ICB.
resultsWe identified PINK1 as a key mediator of ICB resistance in HCC. We found that PINK1 expression was significantly reduced in ICB-resistant HCC and a reduced PINK1 signature was associated with poorer clinical outcomes in patients with HCC. Importantly, PINK1 deficiency serves as a predictive biomarker for diminished responsiveness to immunotherapy. Function experiments have revealed that PINK1 regulates HCC progression and infiltration and activation of neutrophils and T cells. Mechanistically, the tumor cell-intrinsic downregulation of PINK1 activated the production of chemokines involved in neutrophil recruitment, and tumor-infiltrating neutrophils inhibited T cell activity. Additionally, a neutrophil-depleting antibody resensitized tumors to antiprogrammed death-ligand 1 therapy in orthotopic HCC models, further demonstrating that neutrophils are the primary population responsible for the adaptation of cancer cells with reduced PINK1 to ICB-induced immune attacks.
conclusionsOur study uncovered PINK1 as both a predictor of the ICB response and a key mediator of immune evasion by promoting neutrophil infiltration. These results highlight that the therapeutic targeting of neutrophils may represent a viable strategy to overcome ICB resistance in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.